PRF Technologies (PRFX) Capital Expenditures (2020 - 2024)
PRF Technologies (PRFX) posted quarterly Capital Expenditures of -$5000.0 for Q2 2024, up 28.57% on a QoQ basis from -$7000.0 in Q1 2024.
PRF Technologies (PRFX) Capital Expenditures (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has reported Capital Expenditures for 5 consecutive years, with -$5000.0 the latest figure, recorded in Q2 2024.
- Quarterly Capital Expenditures changed N/A year-over-year to -$5000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was -$3000.0 (changed N/A YoY) and the FY2025 annual result came in at $2000.0, down 84.62% from the prior year.
- Capital Expenditures climbed to -$5000.0 in Q2 2024 per PRFX's latest filing, from -$7000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for PRFX reached as high as $240000.0 in Q1 2022 and fell as low as -$243000.0 in Q2 2022.
- A 5-year average of -$1272.7 and a median of -$6000.0 in 2021 frame the typical range for Capital Expenditures.
- The largest YoY upside for Capital Expenditures was 1946.15% in 2022 against a maximum downside of 8000.0% in 2022.
- Year by year, Capital Expenditures stood at -$58000.0 in 2020, then soared by 224.14% to $72000.0 in 2021, then slumped by 437.5% to -$243000.0 in 2022, then soared by 107.0% to $17000.0 in 2023, then sank by 129.41% to -$5000.0 in 2024.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$5000.0, -$7000.0, and $17000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Jun 30, 2022 | -243,000.00 |
| Jun 30, 2022 | -243,000.00 |
| Mar 31, 2022 | 240,000.00 |
| Mar 31, 2022 | 240,000.00 |
| Dec 31, 2021 | 72,000.00 |
| Dec 31, 2021 | 72,000.00 |
| Sep 30, 2021 | -6,000.00 |
| Sep 30, 2021 | -6,000.00 |
| Jun 30, 2021 | -3,000.00 |
| Jun 30, 2021 | -3,000.00 |
| Mar 31, 2021 | -13,000.00 |
| Mar 31, 2021 | -13,000.00 |